Comparative Bioequivalence Study of Ciprofloxacin 500 mg Tablets

Comparative Bioequivalence Study of Ciprofloxacin 500 mg Tablet Manufactured by Pursina Pharmaceutical Company with Innovative Company

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231108059993N13

Enrollment

Registered

2026-02-06

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers were enrolled in the study..

Interventions

Intervention group: The first intervention group, which has been randomly and Single-blindly selected, will take the Iranian Ciprofloxacin 500 mg tablet, and the second group will take a brand drug.

Eligibility

Sex/Gender

Male

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Good general health (liver, heart, and kidneys). Body mass index (18-28). Informed consent Ages range (18-55 years).

Exclusion criteria

Exclusion criteria: Addiction to alcohol, drugs and cigarettes Allergy to Ciprofloxacin Chronic disease treatment history

Design outcomes

Primary

Measure	Time frame
Drug Plasma Concentration. Timepoint: 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24. Method of measurement: Liquid chromatography with dual mass spectrometer (LC/M?S/MS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Ghanbarzadeh

Tabriz University of Medical Sciences

s_ghanbarzadeh@yahoo.com+98 41 3383 2649

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026